Labeling Rule Requires Sponsors To Start Safety Discussions With FDA Earlier
Sponsors will need to discuss safety updates to product labeling in the new format ahead of a submission to the agency in order to facilitate the prior approval necessary under the physician labeling rule
You may also be interested in...
FDA's implementation timeline for the physician labeling rule may mean that advent of the new labeling format will have limited impact on currently available competing products
FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications
Interim data from SHARP and IMPROVE-IT trials fail to show evidence of impact on cancer rates.